Health ❯ Medicine ❯ Pharmaceuticals

Weight Loss

GLP-1 Drugs Ozempic Mounjaro GLP-1 Medications Clinical Trials Semaglutide Orforglipron GLP-1 Receptor Agonists GLP-1 Agonists Retatrutide Wegovy Obesity Tirzepatide Weight Loss Medications Oral Medications Obesity Treatments Drugs Effectiveness Comparison Drug Comparison Amycretin Weight Loss Jabs Slimming Injections Drug Safety Pregnancy Prescription Medications Obesity Treatment Ozempic, Wegovy, Mounjaro Anti-Obesity Drugs Weight Loss Drugs Medications Controversies GLP-1 Treatments

Lilly Will Seek FDA Approval for Retatrutide in Q1 2027 After Two More Positive Phase 3 Trials

Unclear cardiovascular signals together with unfinished manufacturing checks could shape regulators' verdict on Lilly's application.

Generics and Pills Expand Access to GLP‑1s, but Uptake and Coverage Remain Uneven

FDA-Cleared Wegovy Pill Becomes First Oral GLP-1 for Weight Loss

Terry Dubrow Claims GLP-1 Weight Loss Can Produce an 'Ozempic Penis'

Amgen Advances Monthly Obesity Drug to Phase 3 After 20% Weight Loss in Mid-Stage Trial

New Oral β2 Agonist Preserves Muscle in Early Weight-Loss Trials

Eli Lilly’s Oral GLP-1 Pill Matches Injectables in Weight and Blood Sugar Control